对于围性克罗恩病的管理来说,这是新的武器
Clelia Cicerone1, Paulo Gustavo Kotze2
1Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, 20132, Milan, Italy.
Best practice & research. Clinical gastroenterology
|August 6, 2025
概括
对于克罗恩氏病中围囊的新兴治疗方法.
科学领域:
- 胃肠病学和免疫学研究专注于炎症性肠道疾病.
背景情况:
- 周围囊影响~40%的克罗恩氏病 (CD) 患者由于肠道炎症.
- 尽管目前治疗方面取得了进展,反复出现的近囊仍然是一个重大挑战.
- 周边克罗恩病 (CD) 需要新的管理策略.
研究的目的:
- 审查和讨论新的治疗策略,用于围抽性克罗恩病.
- 探索新兴的生物药物,外科手术技术和复杂的围性CD的组合疗法.
主要方法:
- 关于近期关于围性抽性CD的最新研究的综合文献综述.
- 对新出现的治疗目标和治疗方式的分析.
- 综合有关新生物制剂,外科创新和综合治疗方法的数据.
主要成果:
- 确定有前途的新生物病原体,针对特定的炎症途径.
- 概述了用于管管理的最小侵入性手术技术的进步.
- 讨论结合不同治疗方式的潜在好处.
结论:
- 新的生物药物和外科手术策略为管理近管的CD提供了新的希望.
- 组合疗法可以为耐火病例提供增强的疗效.
- 持续的研究对于优化治疗结果至关重要,在具有挑战性的围性CD病例中.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
213
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
213
Inflammatory Bowel Disease IV: Pharmacological Management
190
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
190
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Ulcerative Colitis in IBD
238
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
238


